AIXG Stock News 14.53 05/13/2014 15:43:50 Aixtron Se (AIXG)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aixtron Se (AIXG) 14.53 $AIXG

Stock Futures Sharply Higher; Cummins, Buffalo Wild Wings Up
at Investor's Business Daily - Tue Apr 29, 8:01AM CDT
Stock futures traded higher before Tuesday's open, mirroring Monday's premarket trade that prefaced a wildly volatile session. Dow futures rose 65.3 points above fair market value. Nasdaq 100 futures held tight to a 17.1-point gain and S&P 500...

Upgrade Alert for Aixtron (AIXG)
Comtex SmarTrend(R) - Thu Apr 24, 7:04AM CDT
Aixtron (NASDAQ:AIXG) was upgraded from Underweight to Neutral at HSBC today. The stock closed yesterday at $15.68 on volume of 63,000 shares, below average daily volume of 79,000. Over the past year, Aixtron has traded in a range of $12.44 to $18.06 and closed yesterday at $15.68, 26% above that low. In the last five trading sessions, the 50-day moving average (MA) has climbed 0.2% while the 200-day MA has remained constant.

Aixtron Has Returned 14.1% Since SmarTrend Recommendation (AIXG)
Comtex SmarTrend(R) - Tue Mar 25, 9:45AM CDT
SmarTrend identified an Uptrend for Aixtron (NASDAQ:AIXG) on December 30th, 2013 at $14.58. In approximately 3 months, Aixtron has returned 14.10% as of today's recent price of $16.63.

Shares of AIXG Up 17.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 17, 11:16AM CDT
SmarTrend identified an Uptrend for Aixtron (NASDAQ:AIXG) on December 30th, 2013 at $14.58. In approximately 3 months, Aixtron has returned 17.74% as of today's recent price of $17.16.

Semi-Annual Changes to the NASDAQ Clean Edge Green Energy Index
GlobeNewswire - Mon Mar 17, 6:40AM CDT
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the semi-annual evaluation of the NASDAQ Clean Edge Green Energy Index (Nasdaq:CELS), which will become effective prior to market open on Monday, March 24, 2014.

Downgrade Alert for Aixtron (AIXG)
Comtex SmarTrend(R) - Tue Mar 11, 6:58AM CDT
Aixtron (NASDAQ:AIXG) was downgraded from Outperform to Neutral at Exane BNP Paribas today. The stock closed yesterday at $17.73 on volume of 104,000 shares, below average daily volume of 153,000. Aixtron AG engineers and manufactures metal organic chemical vapor deposition (MOCVD) equipment for the semiconductor industry. The Company's customers use its equipment to produce compound semiconductor layer structures for use in LED, laser, solar cell, transistor, telecommunications, and other applications. Aixtron markets its products worldwide.

20.8% Return Seen to Date on SmarTrend Aixtron Call (AIXG)
Comtex SmarTrend(R) - Mon Mar 10, 9:58AM CDT
SmarTrend identified an Uptrend for Aixtron (NASDAQ:AIXG) on December 30th, 2013 at $14.58. In approximately 2 months, Aixtron has returned 20.82% as of today's recent price of $17.61.

Uptrend Call Working As Aixtron Stock Rises 12.0% (AIXG)
Comtex SmarTrend(R) - Mon Mar 03, 9:29AM CST
SmarTrend identified an Uptrend for Aixtron (NASDAQ:AIXG) on December 30th, 2013 at $14.58. In approximately 2 months, Aixtron has returned 12.04% as of today's recent price of $16.33.

Uptrend Call Working As Aixtron Stock Rises 9.4% (AIXG)
Comtex SmarTrend(R) - Thu Feb 13, 9:34AM CST
SmarTrend identified an Uptrend for Aixtron (NASDAQ:AIXG) on December 30th, 2013 at $14.58. In approximately 2 month, Aixtron has returned 9.43% as of today's recent price of $15.95.

13.9% Return Seen to Date on SmarTrend Aixtron Call (AIXG)
Comtex SmarTrend(R) - Fri Dec 13, 9:18AM CST
SmarTrend identified a Downtrend for Aixtron (NASDAQ:AIXG) on October 7th, 2013 at $15.82. In approximately 2 months, Aixtron has returned 13.88% as of today's recent price of $13.62.

Downtrend Call Working As Aixtron Stock Falls 16.2% (AIXG)
Comtex SmarTrend(R) - Wed Nov 13, 9:32AM CST
SmarTrend identified a Downtrend for Aixtron (NASDAQ:AIXG) on October 7th, 2013 at $15.82. In approximately 1 month, Aixtron has returned 16.16% as of today's recent price of $13.26.

What Does Wall Street See for Aixtron SE's Q2?
Seth Jayson, The Motley Fool - Motley Fool - Mon Jul 22, 12:12AM CDT
Aixtron SE ( NASDAQ: AIXG ) is expected to report Q2 earnings on July 25. Here's what Wall Street wants to see: The 10-second takeaway Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict...

Aixtron Up 13.6% Since SmarTrend Uptrend Call (AIXG)
Comtex SmarTrend(R) - Fri Jun 14, 11:12AM CDT
SmarTrend identified an Uptrend for Aixtron (NASDAQ:AIXG) on April 26th, 2013 at $14.63. In approximately 2 months, Aixtron has returned 13.60% as of today's recent price of $16.62.

Aixtron Has Returned 22.4% Since SmarTrend Recommendation (AIXG)
Comtex SmarTrend(R) - Thu May 30, 4:57PM CDT
SmarTrend identified an Uptrend for Aixtron (NASDAQ:AIXG) on April 26th, 2013 at $14.63. In approximately 1 month, Aixtron has returned 22.42% as of today's recent price of $17.91.

JKF, CYD, ALGN, APAGF, AIXG, DSW Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue May 28, 4:28AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of iShares Morningstar Large Value Index Fund (NYSE:JKF), China Yuchai International Ltd (NYSE:CYD), ALIGN TECHNOLOGY, INC. (NASDAQ:ALGN), Apco Oil and Gas International Inc (NASDAQ:APAGF), Aixtron SE (NASDAQ:AIXG), DSW Inc (NYSESW) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading